Beyond Air, Inc. Q3 2026 Earnings Recap

XAIR Q3 2026 February 13, 2026

Get alerts when XAIR reports next quarter

Beyond Air reported a remarkable 105% year-over-year revenue increase to $2.2 million, driven by growing adoption of its LungFit PH system, and strategically strengthened its balance sheet through the sale of its NeuroNOS subsidiary.

Earnings Per Share Miss

$-0.85 vs $-0.75 est.

-13.3% surprise

Revenue Beat

2194000 vs 2153325 est.

+1.9% surprise

Market Reaction

1-Day +2.86%

5-Day -3.81%

30-Day -21.48%

See XAIR alongside your other holdings

Add to your portfolio — free

Key Takeaways

Achieved significant revenue growth, with quarterly revenue reaching $2.2 million, reflecting strong market demand and increased hospital adoption.
Over 45 hospitals currently utilize the first-generation LungFit PH system, with customer retention exceeding 90%.
Completed the initial sale of LungFit PH to a VA Medical Center, marking a key milestone in expanding the company’s presence in federal healthcare systems.
Expanded international distribution, now covering 40 countries, enhancing the company’s global footprint for long-term growth.
Preparing for the anticipated FDA approval of the second-generation LungFit PH system, expected to enhance market reach and operational efficiency.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit XAIR on AllInvestView.